Radiation boost may help stem cell transplants beat tough leukemia
NCT ID NCT03121014
First seen Jan 19, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can help prevent relapse in people with high-risk acute myeloid leukemia or myelodysplastic syndromes. About 38 adults aged 18–65 will receive the combined treatment. The main goal is to see if more patients survive one year without their cancer returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fludarabine, Busulfan, ATG, Tacrolimus, and total marrow irradiation
What this could lead to
If successful, this could improve the chance of staying cancer-free after a stem cell transplant for people with hard-to-treat leukemia or myelodysplastic syndromes.
What could go wrong
This is a small, early-phase study (38 participants) with no control group. The intense treatment carries serious risks like infection, organ damage, and graft-versus-host disease. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.